Abstract: The present application provides novel DNA methylation markers for detecting the presence or increased risk of developing diabetic kidney disease (DKD) in a subject having diabetes. The present application also provides methods and kits of diagnosing or predicting diabetic kidney disease (DKD) or a risk of suffering from DKD with these DNA methylation markers.

Abstract: Provided herein are biomarkers useful for determining frailty, a biomarker signature for frailty, and methods of using the biomarkers to identify, classify, and treat a subject having frailty. Provided herein are also biomarkers useful for determining, identifying, classifying, and treating conditions associated with altered physical reserve, physical fitness, and exercise capacity.

Abstract: The present invention provides a method for assessing the presence and risk of developing type 2 diabetes, cancer of all sites, or cardiovascular disease in a subject by detecting sequence variation in one or more genes such as carboxypeptidase E (CPE) and insulin degradation enzyme (IDE). A kit, array, and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes, cancer of all sites, or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.

Abstract: The present invention provides a method for assessing the presence and risk of developing type 2 diabetes or cardiovascular disease in a subject by detecting sequence variation in DACH1 (Dachshund homolog 1) gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.

Abstract: The present invention provides a method for assessing the presence and risk of developing type 2 diabetes, cancer of all sites, or cardiovascular disease in a subject by detecting sequence variation in one or more genes such as carboxypeptidase E (CPE) and insulin degradation enzyme (IDE). A kit, array, and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes, cancer of all sites, or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.

Abstract: The present invention provides a method for assessing the presence and risk of developing type 2 diabetes or cardiovascular disease in a subject by detecting sequence variation in DACH1 (Dachshund homolog 1) gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.

Abstract: The present invention provides a method for assessing the presence and risk of developing type 2 diabetes or cardiovascular disease in a subject by detecting sequence variation in DACH1 (Dachshund homolog 1) gene. A kit and device useful for such a method are also provided. In addition, the present invention provides a method for treating type 2 diabetes or cardiovascular disease in patients who have been tested and shown to have the pertinent genetic variations.

Abstract: A method for diagnosing a genetic predisposition in a subject for diseases, disorders or conditions including a diabetic kidney complication such as kidney disease of type 2 diabetes or type 1 diabetes, end stage renal disease (ESRD) due to type 2 diabetes, ESRD due to hypertension in type 2 diabetes, ESRD due to type 1 diabetes; cardiovascular diseases due to type 2 diabetes or type 1 diabetes such as atherosclerotic peripheral vascular disease, hypertension, ischemic cardiomyopathy, and myocardial infarction due to type 2 diabetes or type 1 diabetes; and cerebrovascular accident due to type 2 diabetes. At least one polynucleotide is analyzed to detect a single nucleotide polymorphism (SNP), in which the presence of the single nucleotide polymorphism indicates that the subject is suffering from, at risk for, or suspected of suffering from the diseases, disorders or conditions. Also provided is an array or kit for diagnosing the genetic predisposition.